Assets/KVUED

DORRS MARKET INTELLIGENCE

Kenvue Inc. Dinari dShares

KVUEDEquityDinari
Open terminal ↗
Token price—No pricing observation available
Token market capitalization—Token market cap not supplied
Circulating supply0DORRS issuer token data
Fully diluted valuation (FDV)$0DORRS issuer token data
Reported deployment value—DORRS valuation basis

ASSET PROFILE

Business description

CDI CDI-9838899720

Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026. Kenvue Inc. Dinari dShares provides blockchain-based exposure to the listed underlying security KVUE. Dinari represents that each dShare is backed 1:1 by the corresponding underlying security and supports on-chain transfer, settlement, redemption, and applicable corporate actions.

TRADING ACTIVITY

Last-sale transactions

Reported executions
↗

No last-sale activity to display

Executed transactions will appear here when reported by a connected source.